GV1001 was the first TERT peptide vaccine to be evaluated in clinical trials against advanced pancreatic cancer, lung carcinoma, melanoma, and liver carcinoma [227,232,238,239,240,241,242,243]. This evidence concerns the gene TERT and hepatocellular carcinoma.